Multi-Kinase Inhibitor with Anti-p38γ Activity in Cutaneous T-Cell Lymphoma

Current cutaneous T-cell lymphoma (CTCL) therapies are marked by an abbreviated response, subsequent drug resistance, and poor prognosis for patients with advanced disease. An understanding of molecular regulators involved in CTCL is needed to develop effective targeted therapies. One candidate regu...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xu Hannah, Nam, Sangkil, Wu, Jun, Chen, Chih-Hong, Liu, Xuxiang, Li, Hongzhi, McKeithan, Timothy, Gong, Qiang, Chan, Wing C., Yin, Hongwei Holly, Yuan, Yate-Ching, Pillai, Raju, Querfeld, Christiane, Horne, David, Chen, Yuan, Rosen, Steven T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7269016/
https://www.ncbi.nlm.nih.gov/pubmed/29758280
http://dx.doi.org/10.1016/j.jid.2018.04.030

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7269016/
https://www.ncbi.nlm.nih.gov/pubmed/29758280
http://dx.doi.org/10.1016/j.jid.2018.04.030

Ejemplares similares